Human Stem Cell Derived Cardiomyocytes酶试剂盒Takara

发表于由

Human Stem Cell Derived Cardiomyocytes
品牌 Code No. 产品名称 包装量 价格（元） 说明书 数量
Cellartis Y10060 Cellartis® Pure hES-CM 1 Kit ￥14,296 Human Stem Cell Derived Cardiomyocytes Human Stem Cell Derived Cardiomyocytes Human Stem Cell Derived Cardiomyocytes
Cellartis Y10075 Cellartis® Cardiomyocytes (from ChiSPC22) Kit 1 Kit ￥14,296 Human Stem Cell Derived Cardiomyocytes Human Stem Cell Derived Cardiomyocytes Human Stem Cell Derived Cardiomyocytes
收藏产品 加入购物车

无标题文档

人ES细胞来源心肌细胞
(Cardiomyocytes Derived from Human Embryonic Pluripotent Stem Cells)
Cellartis Pure Cardiomyocytes (from SA121) 是由基因工程技术改良的人ES细胞株（SA121-cTnT）分化而来的心肌细胞，纯度高（约 90%），可进行维持培养。
 
人iPS细胞来源心肌细胞
(Cardiomyocytes Derived from Human Induced Pluripotent Stem Cells)
Cellartis Cardiomyocytes是从人iPS细胞（细胞株ChiPSC22）分化来的高度同质、均一的心肌细胞。本产品与人心肌细胞高度相似，是由iPS细胞分化来的表现出自发搏动能力的心肌细胞。本产品在科研界和药物研发公司广泛采用。
 
■ 产品特点
· Electrophysiological profile highly resembling adult human primary cardiomyocytes
· Respond as expected to cardiac stimuli
· Genetically unmodified cell line derived without selection（Y10075）
· Cells are provided with basal media for thawing and culture
 
■ 产品应用
· Safety pharmacology
· Cardiotoxicity testing
· Discovery of novel cardiac drug targets
· Phenotypic screening
· High-content analysis (HCA)
 
Code No. Product Size
Y10060 Cellartis® Pure Cardiomyocytes (from SA121) Kit 1 Kit
Y10062 Cellartis® CM Thawing Base 32 mL
Y10063 Cellartis® CM Culture Base 90 mL
Y10075 Cellartis® Cardiomyocytes (from ChiPSC22) Kit 1 Kit
 
■ 产品详情请点击：Human Stem Cell Derived Cardiomyocytes
 
[ 确定Cellartis心肌细胞标志物的表达 ]：
Human Stem Cell Derived Cardiomyocytes Human Stem Cell Derived Cardiomyocytes Human Stem Cell Derived Cardiomyocytes
 
[Cellartis 心肌细胞的动作电位]：
Human Stem Cell Derived Cardiomyocytes
 
参考文献：
1. Synnergren J et al.Molecular signature of cardiomyocyte clusters derived from human embryonic stem cells.Stem Cells 2008 Jul; 26(7): 1831-1840.
2. Jonsson MK et al. Quantified Proarrhythmic Potential of Selected Human Embryonic Stem Cell-derived Cardiomyocytes.Stem Cell Res. 2010 May; 4(3): 189-200.
3. Synnergren J et al. Expression of microRNAs and their target mRNAs in human stem cell derived cardiomyocyte clusters and in heart tissue. Physiol. Genomics 2011 May 1; 43(10): 581-594.
4. Nalos L et al. Comparison of the IKr blockers, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes.Br. J. Pharmacol. 2012 Jan; 165(2): 467-478.
5. Synnergren J et al. Global transcriptional profiling reveals similarities and differences between human stem cell-derived cardiomyocyte clusters and heart tissue. Physiol. Genomics 2012 Feb 27; 44(4): 245-258.
6. Yamazaki K et al. A novel method of selecting human embryonic stem cell-derived cardiomyocyte clusters for assessment of potential to influence QT interval. Toxicol. In Vitro. 2012 Mar; 26(2): 335-342.
7. Jonsson MK et al. Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG. J. Mol. Cell Cardiol. 2012 May; 52(5): 998-1008.
8. hnke et al. A novel 3D label-free monitoring system of hES-derived cardiomyocyte clusters: a step forward to in vitro cardiotoxicity testing. PLoS One 2013 Jul ;8(7).
9. Yamazaki et al. Beat-to-Beat Variability in Field Potential Duration in Human Embryonic Stem Cell-Derived Cardiomyocyte Clusters for Assessment of Arrhythmogenic Risk, and a Case Study of Its Application. Pharmacol. & Pharm, 2014, 5, 117-128.